FY2025 · ended Dec 31, 2025 · Revenue $257,612, +4.6% YoY · Filed May 20, 2026
Nutra Pharma Corp. (NPHC) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $257,612 and a net loss of $2.0 million. Free cash flow was -$1.2 million. As of Jun 30, 2026 it held $37,600 in cash and investments and $12.6 million in total debt.
Revenue (TTM)
$160,815
-49.0% vs year-ago TTM
Net income (TTM)
$-5.42M
-255.0% vs year-ago TTM
Operating cash flow (TTM)
$-1.05M
-23.1% vs year-ago TTM
Free cash flow
$-1.19M
-45.0% vs prior year
EPS (TTM)
$-0.00
-244.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
7.16B
+0.0% vs prior year
Net cash
$-12.54M
as of Jun 30, 2026
Operating margin
-1017.8%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NPHC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1119643
- Former names
- CYBER VITAMIN COM (until Feb 28, 2002)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $257,612 | $246,309 | $205,564 | $145,800 | $97,735 |
| Operating income | -$1.5M | -$878,421 | -$886,979 | -$1.9M | -$2.0M |
| Net income | -$2.0M | -$1.3M | -$1.4M | $8.2M | -$13.1M |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Operating cash flow | -$1.2M | -$423,959 | -$550,036 | -$762,432 | -$1.7M |
| Free cash flow | -$1.2M | — | — | -$820,425 | -$1.8M |
| Total assets | $584,558 | $599,495 | $640,397 | $754,913 | $780,022 |
| Total liabilities | $17.4M | $15.4M | $14.4M | $13.1M | $21.7M |
| Stockholders' equity | -$16.8M | -$14.8M | -$13.8M | -$12.4M | -$20.9M |
| Cash and investments | $29,781 | $54,047 | $35,200 | — | — |
| Total debt | $9.8M | $8.7M | $8.6M | $8.4M | $77,673 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change in control
|
Sep 2, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 29, 2026 | Mar 31, 2026 |
| 10-K | Annual report | May 20, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Apr 6, 2026 | Sep 30, 2025 |
| 10-Q | Quarterly report | Mar 25, 2026 | Jun 30, 2025 |
All 349 Nutra Pharma Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.